Opioids and Renal Function

Journal of Pain

Volumn 5, Issue 1, 2004, Pages 2-19

  Mercadante, Sebastiano ^a   Arcuri, Edoardo ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Addiction; Chronic pain; Opioids; Renal failure; Renal function; Transplantation

Indexed keywords

3 [4 METHOXYCARBONYL 4 (N PHENYLPROPIONAMIDO)PIPERIDINO]PROPIONIC ACID; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ALFENTANIL; ASIMADOLINE; BUPRENORPHINE; BUTORPHANOL TARTRATE; CODEINE; DELTA OPIATE RECEPTOR AGONIST; DERMORPHIN; DEXTROPROPOXYPHENE; DIAMORPHINE; FENTANYL; FLUOROURACIL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR AGONIST; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE SULFATE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NIRAVOLINE; OPIATE DERIVATIVE; OXYCODONE; PETHIDINE; REMIFENTANIL; SUFENTANIL; TRAMADOL;

ASCITES; BRADYCARDIA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; DIURESIS; DROWSINESS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GLOMERULONEPHRITIS; GRAND MAL EPILEPSY; GRANULOMATOSIS; HEPATITIS; HUMAN; HYPONATREMIA; HYPOTENSION; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY SCAR; LIVER CIRRHOSIS; LUNG TOXICITY; MALE; MYOCLONUS EPILEPSY; NEUROTOXICITY; NONHUMAN; OLIGURIA; OPIATE ADDICTION; OROFACIAL DYSKINESIA; PAIN ASSESSMENT; RAT; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT; SODIUM EXCRETION; URINE RETENTION; WATER RETENTION;

EID: 1442323946     PISSN: 15265900     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpain.2003.09.007     Document Type: Article

References (170)

1. Alazia M, Levron JC, Guidon C, Badetti C: Pharmacokinetics of fentanyl during continuous infusion in critically ill patients (abstract). Anesthesiology 67:665, 1987
2. Angst MS, Buhrer M, Lotsch J: Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology 92:1473-1476, 2000
3. Arakawa K, Akami T, Okamoto M, Oka T, Nagase H, Matsumoto S: The immunosuppressive effect of delta-opioid receptor antagonist on rat renal allograft survival. Transplantation 53:951-953, 1992
4. Aronin N, Krieger DT: Plamsa immunoreactive B-endorphin is elevated in uraemia. Clin Endocrinol 18:459-464, 1983
5. Arroyo V, Jimenez W: Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 32(suppl):157-170, 2000
6. Asselborn G, Yegles M, Wennig R: Suicide with remifentanil and midazolam: A case report. Acta Clin Belg Suppl 1:54-57, 2002
7. Babul N, Darke AC: Putative role of hydromorphone metabolites in myclonus. Pain 51:260-261, 1992
8. Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 10:184-186, 1995
9. Barnes JN, Goodwin FJ: Dihydrocodeine narcosis in renal failure. BMJ 286:438-439, 1983
10. Barnes JN, Goodwin FJ: Dihydrocodeine in renal failure: Further evidence for an important role of the kidney in the handling of opioid drugs. BMJ 290:740-742, 1985
11. Barreca T, Robaudo C, Cataldi A, Garibaldi A, Cianciosi P, Russo R, Rolandi E, Franceschini R: Plasma beta-endorphin levels and glucose tolerance in patients with chronic renal failure. Biomed Pharmacother 49:283-287, 1995
12. Barnung SK, Treschow M, Borgbjerg FM: Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 71:111-112, 1997
13. Bastani B, Jamal JA: Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 12:2802-2804, 1997
14. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I: Drug prescribing in renal failure: Dosing guidelines for adults. Am J Kidney Dis 3:155-193, 1983
15. Bion JF, Logan BK, Newman PM, Brodie MJ, Oliver JS, Aithison TC, Ledingham IM: Sedation in intensive care: Morphine and renal function. Intensive Care Med 12:359-365, 1986
16. Blaszczyk J, Kedziora J, Luciak M, Sibinska E, Trznadel K, Pawlicki L: Effect of morphine and naloxone on oxidative metabolism during experimental renal ischemia and reperfusion. Exp Nephrol 2:364-370, 1994
17. Bower S: Plasma protein binding of fentanyl: The effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 34:102-106, 1982
18. Bower S, Sear JW: Disposition of alfentanil in patients receiving a renal transplant. J Pharm Pharmacol 41:654-657, 1989
19. Brooks DP, Giardina G, Gellai M, Dondio G, Edwards RM, Petrone G, DePalma PD, Sbacchi M, Jugus M, Misiano P: Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J Pharmacol Exp Ther 266:164-171, 1993
20. Brooks DP, Valente M, Petrone G, Depalma PD, Sbacchi M, Clarke GD: Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs. J Pharmacol Exp Ther 280:1176-1183, 1997
21. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I: Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222-3229, 1998
22. Burgess KR, Burgess EE, Whitelaw WA: Impaired ventilatory response to carbon dioxide in patients with chronic renal failure: Implications for the intensive care unit. Crit Care Med 22:413-419, 1994
23. Cabral AM, Varner KJ, Kapusta DR: Renal excretory responses produced by central administration of opioid agonists in ketamine and xylazine-anesthetized rats. J Pharmacol Exp Ther 282:609-616, 1997
24. Castiglia YM, Braz JR, Vianna PT, Lemonica L, Vane LA: Effect of high-dose fentanyl on renal function in dogs. Rev Paul Med 115:1433-1439, 1997
25. Chauvin M, Lebrault C, Levron JC, Duvaldestin P: Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 66:53-56, 1987
26. Chen ZR, Somogyi AA, Reynolds G, Bochner F: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 31:381-390, 1991
27. Coral JM, Moore AR, Strunin L: Plasma concentraton of fentanyl in normal surgical patients with severe renal failure. Br J Anaesth 52:101P, 1980
28. Dahaba AA, Oettl K, von Klobucar F, Reibnegger G, List WF: End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. Can J Anaesth 49:369-374, 2002
29. Danno K, Nishiura K, Tanaka M: Increased met-enkephalin plasma levels in hemodialysis patients with or without pruritus. J Dermatol Sci 10:238-340, 1995
30. Das UG, Sasidharan P: Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports. Pediatrics 108:1012-1015, 2001
31. Davies JG, Coombes ID, Kingswood C, Greenwood EF, Street MK: The clearance of morphine and morphine-6-glucuronide in critically ill patients receiving continuous renal replacement therapies. J Pharm Pharmacol 46(suppl 2):1045, 1994
32. Davies G, Kingswood C, Street M: Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 31:410-422, 1996
33. Davis PJ, Stiller RL, Cook DR, Street M: Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. Anesth Analg 67:268-271, 1988
34. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73-83, 2001
35. Deng J, St Clair M, Everett C, Reitman M, Star RA: Buprenorphine given after surgery does not alter renal ischemia/reperfusion injury. Comp Med 50:628-632, 2000
36. De Paepe P, Belpaire FM, Rosseel MT, Buylaert WA: The influence of hemorrhagic shock on the pharmacokinetics and the analgesic effect of morphine in the rat. Fundam Clin Pharmacol 12:624-630, 1998
37. D'Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P: Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: The influence of renal failure. Anesthesiology 81:87-93, 1994
38. Dubs A, Wiedemeier P, Caduff B: Morphine poisoning in chronic kidney failure: Morphine-6-glucuronide as a pharmacologically active morphine metabolite. Dtsch Med Wochenschr 124:896-898, 1999
39. Durant PA, Yaksh TL: Drug effects on urinary bladder tone during morphine-induced inhibition of the micturition reflex in unanesthetized rats. Anesthesiology 68:325-334, 1988
40. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27-33, 1998
41. Edwards DJ, Svensson CK, Visco JP, Lalka D: Clinical pharmacokinetics of pethidine. Clin Pharmacokinet 7:421-433, 1982
42. Fainsinger R, Schoeller T, Boiskin M, Bruera E: Palliative care round: Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 9:53-55, 1993
43. Flores O, Camera LA, Hergueta A, Gallego B, Perez Barriocanal F, Gutkowska J, Lopez Novoa JM: Role of atrial natriuretic factor, hemodynamic changes and renal nerves in the renal effects of intraperitoneal morphine in conscious rats. Kidney Blood Press Res 20:18-24, 1997
44. Fregoneze JB, Antunes-Rodrigues J: Role of opioid peptides and subfornical organ in the renal function of intact and hypophysectomized rats. Physiol Behav 51:287-292, 1992
45. Friedman EA, Tao TK: Disappearance of uremia due to heroin-associated nephropathy. Am J Kidney Dis 25:689-693, 1995
46. Fukuhara M, Matsumura K, Abe I, Fujishima M: Interaction of opioids and vasopressin in central action of angiotensin II in conscious rabbits. Hypertens Res 21:89-95, 1998
47. Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM: Methadone is poorly removed by haemodialysis. Nephrol Dial Transplant 14:254-255, 1999
48. Giacomimi KM, Gibson TP, Levy G: Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients. Clin Pharmacol Ther 27:508-514, 1980
49. Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G: Propoxyphene and norpropoxyphene plasma concentration in the anephric patient. Clin Pharmacol Ther 27:665-670, 1980
50. Grzeszczak W, Zukowska-Szczechowska E, Kokot F: Effect of blockade of opiate receptors by naloxone on lutropin (LH), follitropin (FSH) and testosterone secretion in patients after kidney transplantation. Pol Arch Med Wewn 87:250-257, 1992
51. Grzeszczak W, Zukowska-Szczechowska E, Kokot F: Effect of opioid receptor blockade with naloxone on vasopressin secretion in patients with transplanted kidney. Pol Arch Med Wewn 88:219-224, 1992
52. Grzeszczak W, Zukowska-Szczechowska E, Kokot F: Effect of opioid receptor blockade with naloxone on secretion of atrial natriuretic peptide (ANP) in patients with kidney transplantation. Pol Arch Med Wewn 91:177-183, 1994
53. Guay DRP, Matzke GR, Findlay JWA, Nens P: Codeine parmacokinetics and pharmacodynamics in hemodialysis patients (abstract). Clin Pharmacol Ther 41:222, 1987
54. Gutkowska J, Schiller PW: Renal effects of TAPP, a highly selective mu-opioid agonist. Br J Pharmacol 119:239-244, 1996
55. Hanes SD, Franklin M, Kuhl DA, Headley AS: Prolonged opioid antagonism with naloxone in chronic renal failure. Pharmacotherapy 19:897-901, 1999
56. Hanna MH, D' Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S: Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 70:511-514, 1993
57. Hassan H, Bastani B, Gellens M: Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis 35:146-149, 2000
58. Hasselstrom J, Sawe J: Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24:344-354, 1993
59. Hatzoglou A, Bakogeorgou E, Papakonstanti E, Stournaras C, Emmanouel DS, Castanas E: Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth. J Cell Biochem 63:410-421, 1996
60. Hoke JF, Shlugman D, Dershwitz M, Michalowski P, Malthouse-Dufore S, Connors PM, Martel D, Rosow CE, Muir KT, Rubin N, Glass PS: Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 87:533-541, 1997
61. Honda K, Aibiki M, Ogura S, Umegaki O: Effects of fentanyl on renal sympathetic nerve activity, heart rate and systemic blood pressure in anesthetized rabbits: An evaluation in both rabbits and human. Masui 43:830-839, 1994
62. Hojs R, Sinkovic A: Rhabdomyolysis and acute renal failure following methadone abuse. Nephron 62:362, 1992
63. Houdret N, Asnar V, Szostak-Talbodec N, Leteurtre E, Humbert L, Lecomte-Houcke M, Lhermitte M, Paris JC: Hepatonephritis and massive ingestion of buprenorphine. Acta Clin Belg Suppl 1:29-31, 1999
64. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, Reidenberg MM: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13:180-185, 1982
65. Kaiko RF, Benzinger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD: Pharmacokinetic-pharmacodynamic relationship of controlled-release oxycodone. Clin Pharmacol Ther 59:52-61, 1996
66. Kapasi AA, Gibbons N, Mattana J, Singhal PC: Morphine stimulates mesangial cell TNF-alpha and nitrite production. Inflammation 24:463-476, 2000
67. Kapusta DR, Obih JC, Dibona GF: Central mu opioid receptor-mediated changes in renal function in conscious rats. J Pharmacol Exp Ther 265:134-143, 1993
68. Kapusta DR, Obih JC: Central kappa opioid receptor-evoked changes in renal function in conscious rats: Participation of renal nerves. J Pharmacol Exp Ther 267:197-204, 1993
69. Kapusta DR, Dzialowski EM: Central mu opioids mediate differential control of urine flow rate and urinary sodium excretion in conscious rats. Life Sci 56:PL243-48, 1995
70. Kapusta DR, Obih JC: Role of endogenous central opioid mechanisms in maintenance of body sodium balance. Am J Physiol 268:R723-730, 1995
71. Kapusta DR, Obih JC: Central kappa opioids blunt the renal excretory responses to volume expansion by a renal nerve-dependent mechanism. J Pharmacol Exp Ther 273:199-205, 1995
72. Kapusta DR: Opioid mechanisms controlling renal function. Clin Exp Pharmacol Physiol 22:891-902, 1995
73. Kapusta DR, Sezen SF, Chang JK, Lippton H, Kenigs VA: Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci 60:PL15-21, 1997
74. Kapusta DR, Kenigs VA: Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. Am J Physiol 277:R987-995, 1999
75. Kirkham SR, Pugh R: Opioid analgesia in uraemic patients. Lancet 345:1185, 1995
76. Kirvela M, Lindgren L, Seppala T, Olkkola KT: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13-18, 1996
77. Koehntop DE, Rodman JH: Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 17:746-752, 1997
78. Koehntop DE, Noormohamed SE, Fletcher CV: Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. Pharmacotherapy 14:592-599, 1994
79. Kramer HJ, Uhl W, Ladstetter B, Backer A: Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 50:227-235, 2000
80. Jamal JA, Joh J, Bastani B: Removal of morphine with the new high-efficiency and high-flux membranes during haemofiltration and haemodialfiltration. Nephrol Dial Transplant 13:1535-1537, 1998
81. Jiraki K: Lethal effects of normeperidine. Am J Forensic Med Pathol 13:42-43, 1992
82. Joh J, Sila MK, Bastani B: Nondialyzability of fentanyl with high-efficiency and high-flux membranes. Anesth Analg 86:447, 1998
83. Jusko WJ, Gretch M: Plasma and tissue protein binding of frugs in pharmacokinetics. Drug Metab Rev 5:140-143, 1976
84. Larbi EB: Drug induced rhabdomyolysis: case report. East Afr Med J 74:829-831, 1997
85. Lazowski T: The influence of the type of anaesthesia on postoperative pain after kidney transplantation. Ann Transplant 5:28-29, 2000
86. Lee CR, McTavich D, Sorkin EM: Tramadol. Drugs 46:313-340, 1993
87. Lee PC, Hung CJ, Lei HY, Tsai YC: Suspected acute post-transplant neuropsychosis due to interaction of morphine and cyclosporin after a renal transplant. Anaesthesia 5:827-828, 2000
88. Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 15:26-34, 2001
89. Lehmann KA, Sipakis K, Gasparini R, van Peer A: Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. Acta Anaesthesiol Scand 37:176-180, 1993
90. Li Y, Looney GA, Kimler BF, Hurwitz A: Opiate effects on 5-fluorouracil disposition in mice. Cancer Chemother Pharmacol 39:273-277, 1997
91. Lingappa VR: Renal disease, in McPhee S, Lingappa VR, Ganong WF, Lange JD (eds): Pathophysiology of Disease. Stamford, Connecticut, Appleton & Lange, 1995, pp 374-396
92. Linner KM, Stickney BJ, Quist HE, Sharp BM, Portoghese PS: The delta1-opioid receptor antagonist, 7-(benzospiroindanyl)naltrexone [correction of 7-benzylspiroindanylnaltrexone], prolongs renal allograft survival in a rat model. Eur J Pharmacol 354:R3-5, 1998
93. Lynn KL, Pickering W, Gardner J, Bailey RR, Robson RA: Intravenous drug use and glomerular deposition of lipid-like material. Nephron 80:274-276, 1998
94. Marinella MA: Meperidine-induced generalized seizures with normal renal function. South Med J 90:556-558, 1997
95. Matzke GR, Chan GLC, Abrahim PA: Codeine dosage in renal failure. Clin Pharm 5:15-16, 1996
96. Matzke GR, Frye RF, Alexander AC, Reynolds R, Dixon R, Johnston J, Rault RM: The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. J Clin Pharmacol 36:144-151, 1996
97. Mazoit JX, Sandouk P, Scherrmann JM, Roche A: Extra-hepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 48:613-618, 1990
98. Mercadante S, Caligara M, Sapio M, Serretta R, Lodi F: Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 13:241-244, 1997
99. Mercadante S: The role of morphine metabolites in cancer pain. Palliat Med 13:95-104, 1999
100. McQuay HJ, Carroll D, Faura C, Gavaghan DJ, Hand CW, Moore RA: Oral morphine in cancer pain: Influences on morphine and metabolite concentration. Clin Pharmacol Ther 48:236-244, 1990
101. Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM: The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 34:53-59, 1992
102. Milne RW, McLean CF, Mather LE, Nation RL, Runciman WB, Rutten AJ, Somogyi AA: Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep: Importance of the kidney. Drug Metab Dispos 23:334-342, 1995
103. Milne RW, McLean CF, Mather LE, Nation RL, Runciman WB, Rutten AJ, Somogyi AA: Influence of renal failure on the disposition of morphine, morphine-3-glucuronide and morphine-6-glucuronide in sheep during intravenous infusion with morphine. J Pharmacol Exp Ther 282:779-786, 1997
104. Moore KA, Cina SJ, Jones R, Selby DM, Levine B, Smith ML: Tissue distribution of tramadol and metabolites in an overdose fatality. Am J Forensic Med Pathol 20:98-100, 1999
105. Moreau R, Cailmail S, Hamon G, Lebrec D: Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis. J Gastroenterol Hepatol 11:857-863, 1996
106. Moreau K, Morel D, Merville P, Melon B, Potaux L: Cardiorespiratory arrest following ingestion of morphine sulfate in a patient with chronic renal failure. Presse Med 26:713, 1997
107. Mori T, Nishikawa K, Terai T, Yukioka H, Asada A: The effects of epidural morphine on cardiac and renal sympathetic nerve activity in alpha-chloralose-anesthetized cats. Anesthesiology 88:1558-1565, 1998
108. Mosaddeghi M, Kapusta DR, Minor LD, Duan N, Paul D: Effects of kappa-opioid receptor agonists on stimulated phosphoinositide hydrolysis in rat kidney. Eur J Pharmacol 289:411-417, 1995
109. Nagaoka E, Minami K, Shiga Y, Uezono Y, Shiraishi M, Aoyama K, Shigematsu A: Tramadol has no effect on cortical renal blood flow-despite increased serum catecholamine levels-in anesthetized rats: Implications for analgesia in renal insufficiency. Anesth Analg 94:619-625, 2002
110. Nghiem DD: Opiate receptor blockade improves function and survival of high-risk renal allografts. Transplant Proc 25:3195, 1993
111. Odar-Cederlof I, Boreus LO, Bondesson U, Holmberg L, Heyner L: Comparison of renal excretion of pethidine (meperidine) and its metabolites in old and young patients. Eur J Clin Pharmacol 28:171-175, 1985
112. Osborne RJ, Joel SP, Slevin M: Morphine intoxication in renal failure: The role of morphine-6-glucuronide. BMJ 292:1548-1549, 1986
113. Osborne R, Joel S, Trew D, Slevin M: Morphine and metabolite behavior after different routes of administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12-19, 1990
114. Osborne R, Joel S, Grebenik K, Trew D, Slevin M: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54:158-167, 1993
115. Otero A, Esteban J, Martinez J, Cejudo C: Rhabdomyolysis and acute renal failure as a consequence of heroin inhalation. Nephron 62:245, 1992
116. Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T: Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 14:903-909, 1999
117. Peces R, Diaz-Corte C, Baltar J, Seco M, Alvarez-Grande J: Haemolytic-uraemic syndrome in a heroin addict. Nephrol Dial Transplant 13:3197-3199, 1998
118. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, Laina A: Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348:1552-1554, 1996
119. Peterson GM, Randall CTC, Peterson J: Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: Relationship to renal function and route of administration. Eur J Pharmacol 38:121-124, 1990
120. Pfab R, Hirtl C, Zilker T: Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Toxicol Clin Toxicol 37:43-50, 1999
121. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhart J, Layman M, Cerbone DF, Inturrisi CE: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profile, steady-state concentrations and the consequences of renal failure. Pain 47:13-19, 1991
122. Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM: The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 51:422-431, 1992
123. Randall C, Baselt BS, Casarett LJ: Urinary excretion of methadone in man. Clin Pharmacol Ther 13:64-70, 1971
124. Redfern N: Dihydrocodeine overdose treated with naloxone infusion. BMJ 287:751-752, 1983
125. Regnard CFB, Twycross RG: Metabolism of narcotics. BMJ 288:860, 1984
126. Rice EK, Isbel NM, Becker GJ, Atkins RC, McMahon LP: Heroin overdose and myoglobinuric acute renal failure. Clin Nephrol 54:449-454, 2000
127. Richtsmeier AJ Jr, Barnes SD, Barkin RL: Ventilatory arrest with morphine patient-controlled analgesia in a child with renal failure. Am J Ther 4:255-257, 1997
128. Rimoy GH, Bhaskar NK, Wright DM, Rubin PC: Mechanism of diuretic action of spiradoline (U-62066E): A kappa opioid receptor agonist in the human. Br J Clin Pharmacol 32:611-615, 1991
129. Roozen HG, Kan Rd R, Brink Wv W, Kerkhof BJ, Geerlings PJ: Dangers involved in rapid opioid detoxification while using opioid antagonists: Dehydration and renal failure. Addiction 97:1071-1073, 2002
130. Rostami-Hodgean A, Wolff K, Hay A, Raistrick D, Calvert R, Tucker G: Population pharmacokinetics of methadone in opiate users: Characterization of time-dependent changes. Br J Clin Pharmacol 48:43-52, 1999
131. Sagar S, Sorbi D, Arbeit LA, Singhal PC: Morphine modulates 72-kDa matrix metalloproteinase. Am J Physiol 267: F654-659, 1994
132. Saneto RP, Fitch JA, Cohen BH: Acute neurotoxicity of meperidine in an infant. Pediatr Neurol 14:339-341, 1996
133. Sawe J, Odar-Cederlof I: Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 32:377-382, 1987
134. Schenk HD, Radke J, Ensink FB, Drobnik L, Kettler D, Sonntag H, Hellige G, Bretschneider HJ: Interactions between renal and general hemodynamics in fentanyl, droperidol, ketamine, thiopental and in peridural anesthesia: Animal studies. Anaesthesiol Reanim 20:60-70, 1995
135. Sear JW: Sufentanil disposition in patients undergoing renal transplantation: Influence of choice of kinetic model. Br J Anaesth 63:60-67, 1989
136. Segal A, Dowling JP, Ireton HJ, Rhodes HC, Thomas GW, Kerr PG, Spagnolo DV: Granulomatous glomerulonephritis in intravenous drug users: A report of three cases in oxycodone addicts. Hum Pathol 29:1246-1249, 1998
137. Sezen SF, Kenigs VA, Kapusta DR: Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats. J Pharmacol Exp Ther 287:238-245, 1998
138. Shah S, Hardy J: Oxycodone: A review of the literature. Eur J Palliat Care 8:93-96, 2001
139. Shanahan KM, Evans AM, Nation RL: Disposition of morphine in the rat isolated perfused kidney: Concentration ranging studies. J Pharmacol Exp Ther 282:1518-1525, 1997
140. Shen CH, Hung CJ, Wu CC, Huang HW, Ho WM: Rhabdomyolysis-induced acute renal failure after morphine overdose: A case report. Acta Anaesthesiol Sin 37:159-162, 1999
141. Shirasaka T, Kunitake T, Kato K, Takasaki M, Kannan H: Nociceptin modulates renal sympathetic nerve activity through a central action in conscious rats. Am J Physiol 277: R1025-103, 1999
142. Shlugman D, Dufore S, Dershwitz M: Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls. Anesthesiology 81:1417, 1994 (abstract)
143. Scholz J, Steinfath M, Schulz M: Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: An update. Clin Pharmacokinet 31:275-292, 1996
144. Shyu WC, Morgenthien EA, Barbhaiya RH: Pharmacokinetics of butorphanol nasal spray in patients with renal impairment. Br J Clin Pharmacol 41:397-402, 1996
145. Shweta A, Malpas SC, Anderson WP, Evans RG: Effects of naloxone on the haemodynamic and renal functional responses to plasma volume expansion in conscious rabbits. Pflugers Arch 439:150-157, 1999
146. Singhal PC, Pan CQ, Gibbons N, Valderrama E: Effect of morphine on mesangial immunoglobulin G aggregate kinetics. Am J Physiol 265:C1211-1219, 1993
147. Singhal PC, Abramovici M, Bansal M, Jaffer S, Mattana J, Shah R, Gibbons N: Opioids modulate migration, spreading and adherence of mesangial cells. Nephron 68:366-371, 1994
148. Singhal PC, Pamarthi M, Shah R, Chandra D, Gibbons N: Morphine stimulates superoxide formation by glomerular mesangial cells. Inflammation 18:293-299, 1994
149. Singhal PC, Pan CQ, Sagar S, Gibbons N, Valderrama E: Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium. Nephron 70:229-234, 1995
150. Singhal PC, Sagar S, Gibbons N: Morphine modulates cathepsin B and L activity in isolated glomeruli and mesangial cells. Inflammation 19:67-73, 1995
151. Singhal PC, Sharma P, Gibbons N, Franki N, Kapasi A, Wagner JD: Effect of morphine on renomedullary interstitial cell proliferation and matrix accumulation. Nephron 77:225-234, 1997
152. Singhal PC, Sagar S, Reddy K, Sharma P, Ranjan R, Franki N: HIV-1 gp120 envelope protein and morphine-tubular cell interaction products modulate kidney fibroblast proliferation. J Investig Med 46:243-248, 1998
153. Singhal PC, Sharma P, Sanwal V, Prasad A, Kapasi A, Ranjan R, Franki N, Reddy K, Gibbons N: Morphine modulates proliferation of kidney fibroblasts. Kidney Int 53:350-357, 1998
154. Skopp G, Klinder K, Potsch L, Zimmer G, Lutz R, Aderjan R, Mattern R: Postmortem distribution of dihydrocodeine and metabolites in a fatal case of dihydrocodeine intoxication. Forensic Sci Int 95:99-107, 1998
155. Smith MT: Neuroexcitatory effects of morphine and hydrimorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 27:524-528, 2000
156. Somogyi AA, Nation RL, Olweny C, Tsirgiotis P, van Crugten J, Milne RW, Cleary JF, Danz C, Bochner F: Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clin Pharmacokinet 24:413-420, 1993
157. Stock SL, Catalano G, Catalano MC: Meperidine associated mental status changes in a patient with chronic renal failure. J Fla Med Assoc 83:315-319, 1996
158. Szeto HH, Inturrisi E, Houde E, Saal S, Cheigh J, Reidenberg MM: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86:738-741, 1977
159. Sjogren P, Dragsted L, Christensen CB: Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 37:780-782, 1993
160. Talbott GA, Lynn AM, Levy FH, Zelikovic I: Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr (Phila) 36:171-173, 1997
161. Tan AU Jr, Cohen AH, Levine BS: Renal amyloidosis in a drug abuser. J Am Soc Nephrol 5:1653-1658, 1995
162. Trelewicz P, Grzeszczak W, Drabczyk R: Levels of beta-endorphin in serum of patients with chronic renal failure treated with hemodialysis during a test which stimulates hypoglycemia after insulin. Pol Arch Med Wewn 89:217-222, 1993
163. Trelewicz P, Grzeszczak W, Drabczyk R: Serum beta-endorphin in non-dialysed and haemodialysed patients with chronic renal failure. Int Urol Nephrol 26:117-123, 1994
164. Valdovinos Mahave MC, Tejada Artigas A, Ruiz Valero F, Lapetra Labe A: Non-traumatic rhabdomyolysis, compartment syndrome, and acute kidney failure caused by heroin. Rev Clin Esp 197:533-534, 1997
165. Van Crugten JT, Somogyi AA, Nation RL, Reynolds G: The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. Pain 71:199-205, 1997
166. Van Crugten JT, Somogyi AA, Nation RL: Effect of uranyl nitrate-induced renal failure on morphine disposition and antinociceptive response in rats. Clin Exp Pharmacol Physiol 27:74-79, 2000
167. Wang YX, Clarke GD, Sbacchi M, Petrone G, Brooks DP: Contribution of alpha-2 adrenoceptors to kappa opioid agonist-induced water diuresis in the rat. J Pharmacol Exp Ther 270:244-249, 1994
168. Wong NA, Jones HW: An analysis of discharge drug prescribing amongst elderly patients with renal impairment. Postgrad Med J 74:420-422, 1998
169. Yang CC, Yang GY, GerJ, Tsai WJ, Deng JF: Severe rhabdomyolysis mimicking transverse myelitis in a heroin addict. J Toxicol Clin Toxicol 33:591-595, 1995
170. Zukowska-Szczechowska E, Grzeszczak W, Kokot F: Effect of opioid receptor blockade with naloxone on plasma renin activity and aldosterone levels in patients with kidney transplantation. Pol Arch Med Wewn 88:324-329, 1992